Last updated: April 19, 2026
Below is important safety information for medications that may be prescribed through the Phlex Meds platform. This information is not a substitute for professional medical advice from your prescribing physician.
THYROID C-CELL TUMORS: In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, and injection site reactions. These side effects are most common during dose escalation and typically improve over time.
Pancreatitis (acute and chronic), gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury, hypoglycemia (especially when used with insulin or sulfonylureas), diabetic retinopathy complications, anaphylactic reactions, and angioedema. Discontinue if pancreatitis is suspected.
Personal or family history of MTC or MEN 2. Hypersensitivity to semaglutide. Pregnancy and breastfeeding. History of pancreatitis.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Safety information is similar to semaglutide above. Additional considerations include: hypersensitivity reactions, acute pancreatitis, and hypoglycemia. The thyroid C-cell tumor warning also applies to tirzepatide.
CARDIOVASCULAR RISK: Testosterone therapy may increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.
VENOUS THROMBOEMBOLISM: Postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone use. Evaluate patients for VTE risk before and during treatment.
Acne, oily skin, injection site pain, fluid retention, gynecomastia, increased hematocrit/hemoglobin, changes in cholesterol (decreased HDL), mood changes, testicular atrophy, and changes in libido.
Polycythemia (elevated red blood cells), hepatotoxicity, prostate enlargement, sleep apnea (worsening or new onset), cardiovascular events (heart attack, stroke), venous thromboembolism, and psychiatric effects (aggression, mania).
Regular monitoring of: hematocrit/hemoglobin (within 3-6 months of initiation, then annually), lipid panel, PSA (prostate-specific antigen), liver function tests, and testosterone levels. Dose adjustments may be required based on lab results.
Testosterone is a Schedule III controlled substance under the Controlled Substances Act. It is subject to misuse, abuse, and diversion.
Sermorelin is a growth hormone-releasing hormone (GHRH) analog. Common side effects include injection site reactions (pain, redness, swelling), flushing, dizziness, headache, and hyperactivity. Contraindicated in patients with active malignancy. Use with caution in patients with a history of cancer.
NAD+ (Nicotinamide Adenine Dinucleotide) is available as a sublingual supplement. Side effects are generally mild and may include nausea, fatigue, headaches, and stomach discomfort. Consult your provider before use if you are taking other medications.
BPC-157 is a peptide used for regenerative and recovery purposes. It is considered investigational and is not FDA-approved for any medical condition. Side effects may include nausea, dizziness, and injection site reactions. Long-term safety data in humans is limited.
Compounded medications available through Phlex Meds are prepared by licensed compounding pharmacies. These medications are NOT FDA-approved as finished products. They are made using FDA-approved ingredients and are customized to individual patient needs by a licensed pharmacist. Because these medications are customized, they do not undergo the same FDA safety, effectiveness, or manufacturing review as commercially manufactured medications.
If you experience a serious adverse reaction, seek immediate medical attention by calling 911 or visiting the nearest emergency room. You may also report adverse events to the FDA MedWatch program at 1-800-FDA-1088 or www.fda.gov/medwatch.
For safety-related questions: safety@phlexmeds.com